- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 209/20 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
Patent holdings for IPC class C07D 209/20
Total number of patents in this class: 334
10-year publication summary
24
|
26
|
19
|
24
|
33
|
24
|
15
|
38
|
19
|
7
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
On Target Laboratories, LLC | 37 |
11 |
Allergan, Inc. | 2600 |
8 |
Massachusetts Institute of Technology | 9795 |
7 |
Apotex Technologies Inc. | 17 |
6 |
The Johns Hopkins University | 5377 |
5 |
Ajinomoto Co., Inc. | 2337 |
5 |
BELLUS Health Inc. | 19 |
5 |
The Trustees of Columbia University in the City of New York | 3440 |
4 |
Vertex Pharmaceuticals Incorporated | 1581 |
4 |
Ramot at Tel-Aviv University Ltd. | 1370 |
4 |
Heidelberg Pharma Research GmbH | 60 |
4 |
Ústav organické chemie a biochemie AV {hacek over (C)}R, v.v.i. | 6 |
4 |
Shuttle Pharmaceuticals, Inc. | 15 |
4 |
Cybin UK Ltd | 30 |
4 |
California Institute of Technology | 3884 |
3 |
Duke University | 2872 |
3 |
Purdue Research Foundation | 3277 |
3 |
Beyondspring Pharmaceuticals, Inc. | 76 |
3 |
Chromocell Corporation | 51 |
3 |
Givaudan SA | 1760 |
3 |
Other owners | 241 |